GLP-1 Drugs Under Investigation as Potential Treatment for Long COVID
Table of Contents
A new clinical trial is underway to determine if medications already approved for type 2 diabetes and obesity can alleviate the debilitating symptoms of long COVID. The study, led by scientists at Scripps Research, builds on emerging evidence suggesting a broader therapeutic potential for GLP-1 drugs, currently being explored for conditions ranging from cardiovascular disease to addiction.
An estimated 20 million Americans are currently living with long COVID, a complex condition characterized by persistent symptoms like fatigue, brain fog, headache, shortness of breath, and joint and muscle pain. The impact on daily life can be profound, and effective treatments remain elusive.
Scripps Research Launches Nationwide Digital Trial
The digital nature of the trial is designed to maximize accessibility for those impacted by long COVID. “People can do this from their couch or their bed or wherever they are and this is especially important for people with long COVID who have a lot of energy limitations,” explained a senior program director at Scripps Research. The study is open to residents across the continental United States, with materials shipped directly to participants’ homes.
The research will employ a rigorous randomized, double-blind, placebo-controlled methodology. Participants will be divided into two groups: one receiving the GLP-1 drug, and the other receiving a placebo. Neither the participants nor the researchers will know who is receiving which treatment. Check-ins will be conducted via video chat, and participants will utilize a wearable monitoring device – similar to a Garmin watch – to track their weight.
Hope Fueled by Anecdotal Evidence and Broad Therapeutic Potential
The decision to investigate GLP-1 drugs for long COVID stems from growing anecdotal reports. Over the past several years, individuals taking medications like Ozempic and Zepbound for weight management have reported unexpected improvements in other areas of their health. “There have been cases about it helping with autoimmune conditions, decreasing rates of cancer, helping decrease addiction and so we basically don’t fully understand what is happening with these drugs,” a senior official stated.
This broader potential is fueling excitement within the research community. “I really hope that this is the first successful clinical trial that can make a big difference for people with long COVID,” the program director said. Adding a deeply personal dimension to the research, the director shared their own experience: “I myself have had long COVID for five years and I deeply understand how difficult it is. I’m hoping that even just seeing the trial happening now can provide people hope.”
Trial Details and Eligibility
Scripps Research aims to enroll 1,000 participants in the trial. To be eligible, individuals must:
- Be at least 18 years old
- Reside in the United States (excluding Hawaii)
- Possess documentation confirming a diagnosis of long COVID
If successful, researchers anticipate exploring the potential of GLP-1 drugs for other conditions linked to infection. “If it is successful, we would be interested in expanding to other conditions that are infection-associated,” the program director added.
Individuals interested in learning more or participating in the trial can find additional information [here](Click here to learn more about how to participate in the trial.).
Copyright 2025 by WDIV ClickOnDetroit – All rights reserved.
